This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.

The present invention provides for methods and systems for the treatment and diagnosis of Hirschsprung-associated enterocolitis. Treatment of Hirschsprung-associated enterocolitis can include providing and administering an antifungal agent or a combination of an antifungal agent and an antibiotic. Diagnosis of Hirschsprung-associated enterocolitis can include the detection of fungal species by way of qPCR.

This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.

Provided are methods for identifying surface-exposed epitopes of fungal cell wall proteins, and related peptide antigens, suitable for the development of antifungal antibodies. The methods allow for the detection of surface-exposed epitopes that are particularly highly expressed in drug-resistant fungal pathogens, and in pathogens exposed to antifungal drugs. Also provided are antifungal antibodies which may be derived by these methods. The methods and antibodies find use in the treatment of treating and diagnosing fungal infections, such as candidiasis, aspergillosis cryptococcosis, and Mucormycosis.

Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.

The present disclosure provides compositions and methods for treating fungal infections. Disclosed here are proteins (Ait1p) that bind to TORC1 and regulate cell growth in yeast cells. These proteins and agents that bind to them may be effective in treating infection, particularly those caused by yeast, such as Candida glabrata.

Disclosed herein are compositions and methods for treating and immunizing against C. auris infection and colonization. The compositions and methods include polypeptides and fragments derived from the C. albicans Als3 protein, homologs thereof, and antibodies or fragments thereof that specifically bind these polypeptides and fragments. Administration of these compositions confers treatment and resistance against C. auris infection and colonization.

This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.

A method for evaluating biofilm formation on a medical device material in vivo using an invertebrate includes: a step of inserting the medical device material between a hypodermal portion and an intestinal tract of an invertebrate, a step of extracting the medical device material from the invertebrate, and a step of evaluating biofilm formation on the surface of the medical device material; the invertebrate is for use in this evaluation of the biofilm formation.

The invention is directed to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.